|
|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CELLULAR AND MOLECULAR
Department of Pharmacology, Tulane University Health Sciences Center, New Orleans, Louisiana (L.H., B.M.K., J.T.T., M.L.); Department of Medicinal Chemistry, Novo Nordisk A/S, Måløv, Denmark (T.M.T., J.B.H.); Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland (H.Z.); Department of Pharmacology, Medical College of Virginia, Richmond, Virginia (M.Z.); and Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada (D.S.R.).
Mibefradil is a Ca2+ channel antagonist that inhibits both T-type and high-voltage-activated Ca2+ channels. We previously showed that block of high-voltage-activated channels by mibefradil occurs through the production of an active metabolite by intracellular hydrolysis. In the present study, we modified the structure of mibefradil to develop a nonhydrolyzable analog, (1S, 2S)-2-(2-(N-[(3-benzimidazol-2-yl)propyl]-N-methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride (NNC 55-0396), that exerts a selective inhibitory effect on T-type channels. The acute IC50 of NNC 55-0396 to block recombinant
1G T-type channels in human embryonic kidney 293 cells was
7 µM, whereas 100 µM NNC 55-0396 had no detectable effect on high-voltage-activated channels in INS-1 cells. NNC 55-0396 did not affect the voltage-dependent activation of T-type Ca2+ currents but changed the slope of the steady-state inactivation curve. Block of T-type Ca2+ current was partially relieved by membrane hyperpolarization and enhanced at a high-stimulus frequency. Washing NNC 55-0396 out of the recording chamber did not reverse the T-type Ca2+ current activity, suggesting that the compound dissolves in or passes through the plasma membrane to exert its effect; however, intracellular perfusion of the compound did not block T-type Ca2+ currents, arguing against a cytoplasmic route of action. After incubating cells from an insulin-secreting cell line (INS-1) with NNC 55-0396 for 20 min, mass spectrometry did not detect the mibefradil metabolite that causes L-type Ca2+ channel inhibition. We conclude that NNC 55-0396, by virtue of its modified structure, does not produce the metabolite that causes inhibition of L-type Ca2+ channels, thus rendering it more selective to T-type Ca2+ channels.
Address correspondence to: Dr. Ming Li, Department of Pharmacology SL-83, 1430 Tulane Avenue, New Orleans, LA 70112. E-mail: mli{at}tulane.edu
This article has been cited by other articles:
![]() |
L. Zhang, L. P. Renaud, and M. Kolaj Properties of a T-Type Ca2+Channel-Activated Slow Afterhyperpolarization in Thalamic Paraventricular Nucleus and Other Thalamic Midline Neurons J Neurophysiol, June 1, 2009; 101(6): 2741 - 2750. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. H. Bui, A. Quesada, A. Handforth, and O. Hankinson The Mibefradil Derivative NNC55-0396, a Specific T-Type Calcium Channel Antagonist, Exhibits Less CYP3A4 Inhibition than Mibefradil Drug Metab. Dispos., July 1, 2008; 36(7): 1291 - 1299. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Liu and M. T. Shipley Multiple Conductances Cooperatively Regulate Spontaneous Bursting in Mouse Olfactory Bulb External Tufted Cells J. Neurosci., February 13, 2008; 28(7): 1625 - 1639. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Taylor, L. Huang, B. M. Keyser, H. Zhuang, C. W. Clarkson, and M. Li Role of high-voltage-activated calcium channels in glucose-regulated {beta}-cell calcium homeostasis and insulin release Am J Physiol Endocrinol Metab, November 1, 2005; 289(5): E900 - E908. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Isope and T. H. Murphy Low threshold calcium currents in rat cerebellar Purkinje cell dendritic spines are mediated by T-type calcium channels J. Physiol., January 1, 2005; 562(1): 257 - 269. [Abstract] [Full Text] [PDF] |
||||